Ivabradine in the management of elevated resting heart rate associated with mediastinal radiation therapy.

Competing Interests: Disclosures Dr Groarke was an employee of the Division of Cardiovascular Medicine, Brigham and Women’s Hospital, Boston, MA, at the time this research was conducted; outside of and unrelated to the submitted work, Dr Groarke has received research support from Amgen, was previously employed by Amgen, and is currently an employee of Pfizer. Dr Nohria receives research support from Bristol-Myers Squibb and consulting fees from AltaThera Pharmaceuticals, AstraZeneca, Bantam Pharmaceuticals, Regeneron Pharmaceuticals, and Takeda Oncology. Dr Neilan has received advisory fees from AbbVie, Amgen, Genentech, Roche, Bristol Myers Squibb, and Sanofi. Dr Neilan has received grant funding from AstraZeneca and Bristol-Myers Squibb. Dr Novak is an advisor/independent contractor for Dysimmune Diseases Foundation. Dr Novak received royalties from Oxford University Press and owns stocks or stock options in Moderna, Novavax, Editas Medicine, and Pfizer. Dr Itzhaki Ben Zadok, Mr Caron, Dr Redd, and Dr Ng have no conflicts to report.